Background Visual aura (VA) occurs mostly in migraine with aura (MA), but some case studies have reported aura in non-migraine headaches. Thus, information of VA in non-migraine headaches is scarce. Aim of this study was to investigate the prevalence and impact of VA in non-migraine headache and compare it with that of migraine headache. Methods This study was a nationwide population-based study. We used an internet-based headache diagnosis questionnaire to diagnose headache, and various modules to evaluate clinical features and comorbidities of participants with headache. We defined migraine headache as migraine and probable migraine (PM), whereas non-migraine headache was defined as a headache but not migraine or PM. VA was defined as a self-reporting VA rating scale score ≥ 3. Results Of the 3,030 participants, 1,431 (47.2%) and 507 (16.7%) had non-migraine headache and migraine headache, respectively. VA prevalence was much lower in the non-migraine headache group than in the migraine headache group (14.5% [207/1,431] vs. 26.0% [132/507], P < 0.001). In subjects with non-migraine headache, those with VA had a markedly higher number of headache days per 30 days (median [25 th –75 th percentiles]: 2.0 [1.0–5.0] vs. 2.0 [1.0–3.0], P < 0.001), and headache-related disability (6.0 [3.0–16.0] vs. 2.0 [0.0–7.0], P < 0.001) than those without VA. VA prevalence did not differ significantly according to age and sex. Conclusion Non-migraine headache with VA patients had more severe symptoms than those without VA. These findings may improve the understanding of VA and the management of individuals with non-migraine headache.
S29 53.46 billion (US$ 8.6 billion). Besides, the intangible cost was estimated in terms of WTP and utility. Patients with MI reported the highest WTP value among the three patient subgroups, while patients with angina reported a higher WTP value than HF patients. Lower utility scores were observed in IHD patients compared to healthy controls. Factors affecting the costs were determined as age, gender, inpatient days, sub-diagnosis type, insurance type, income and utility of patients. CONCLUSIONS: In summary, our study showed ischemic Heart Disease impose heavy economic burden in China. Our study would provide information for making healthcare policy in resource allocation and planning, as well as further clinical research.
A645and exclusion criteria. The data related to economic model, cost, quality-adjusted life years (QALYs), lost years (LYs), horizon time of study and incremental costeffectiveness ratio (ICER) was extracted. The currency was converted to US$ using purchasing power parities exchange rate. Results: A total of 51 articles were found in primary search, of which 3 studies were met our criteria. The economic model, which applied in all of them was Markov model. The cost effectiveness of standard care with and without Ivabradine were evaluated. The clinical outcomes of these studies were hospitalization rate, adverse effect and mortality rate that have been considered in the Markov model.The medical costs have been calculated in the studies. Furthermore, the time horizon of studies were 10-year and over patient's lifetime. The incremental QALYs, LYs and cost because of adding Ibavradine to standard care had a range of 0.18 to 0.28, 0.14 to 0.25 and -8594 to 4913 dollars. In addition, the maximum amount of ICER was 24920 dollars per QALY. All ICERs were lower than the threshold. ConClusions: Ivabradine added to standard treatment could be regarded as a cost effective option for heart failure therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.